JPMorgan raised the firm’s price target on Ascendis Pharma to $180 from $165 and keeps an Overweight rating on the shares. The firm updated its BioMarin and Ascendis models to reflect yesterday’s “clinical de-risking news” as well as increased market share for TransCon CNP in achondroplasia. More credit will come into Ascendis shares over time and the urgency to own the stock will only build as we near the U.S. Yorvipath launch, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $207 from $178 at Citi
- Ascendis Pharma price target raised to $289 from $264 at Wells Fargo
- Disney, DirecTV agree to restore programming, B+L mulls sale: Morning Buzz
- Morning Movers: Bausch + Lomb surges as said to consider potential sale
- Ascendis Pharma’s Growth Treatment Excels in Trial